Ruben Fragoso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruben Fragoso has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Han Sung Lee
Department of Pathology, University of California, Davis, Sacramento, CA, 95817, USA
2 shared publications - Jonathan W. Riess
Division of Hematology and Oncology, UC Davis School of Medicine, Sacramento, CA 95817, USA
2 shared publications - Oliver Fiehn
West Coast Metabolomics Center, University of California, Davis, Davis, USA
2 shared publications - Orin Bloch
Department of Neurological Surgery, University of California, Davis, Sacramento, CA 95817, USA
2 shared publications - Orwa Aboud
University of California Davis
2 shared publications - Rawad Hodeify
Department of Biotechnology, School of Arts and Sciences, American University of Ras Al Khaimah, Ras Al Khaimah 72603, United Arab Emirates
2 shared publications
Latest Publications
- Open Access
- 9 June 2025
- Published by MDPI AG in Preprints.org
Plasma Lipidomics as a Novel Liquid Biopsy Approach for Glioblastoma
Glioblastoma is an aggressive brain tumor that invariably recurs despite treatment, partly due to metabolic adaptations, including altered lipid metabolism. This study investigates plasma lipidomic profiles in glioblastoma patients to explore their potential as a liquid biopsy for disease monitoring. Plasma samples were collected from 36 patients with histopathologically-confirmed IDH wild-type glioblastoma at four treatment stages: Pre-Surgery (n=36), Post-Surgery (n=32), Pre-Radiation (n=28), and Post-Radiation (n=17). Untargeted lipidomics analysis was performed using liquid chromatography-high resolution mass spectrometry (LC-HR-MS/MS. Plasma lipidomic signatures differed significantly across treatment stages. Specifically, the lipidomic profile prior to surgery was distinct from those at subsequent stages, demonstrating increased compound abundance of numerous lipids prior to surgery that are decreased at subsequent stages, including linolenic acid (fold change 2.58, p=4.21x10-11), behenic acid (fold change 2.09, p=9.3x10-10), and linolenic acid (fold change 4.44, p=5.83x10-6). Random Forest modeling could predict pre-surgical samples with 85.7% accuracy. Plasma lipidomics shows promise as a liquid biopsy approach for monitoring glioblastoma treatment. The distinct lipidomic profile observed prior to surgery suggests potential for early detection.
- 9 June 2025
- Published by MDPI AG in Preprints.org
Open AccessPlasma Lipidomics as a Novel Liquid Biopsy Approach for Glioblastoma
Glioblastoma is an aggressive brain tumor that invariably recurs despite treatment, partly due to metabolic adaptations, including altered lipid metabolism. This study investigates plasma lipidomic profiles in glioblastoma patients to explore their potential as a liquid biopsy for disease monitoring. Plasma samples were collected from 36 patients with histopathologically-confirmed IDH wild-type glioblastoma at four treatment stages: Pre-Surgery (n=36), Post-Surgery (n=32), Pre-Radiation (n=28), and Post-Radiation (n=17). Untargeted lipidomics analysis was performed using liquid chromatography-high resolution mass spectrometry (LC-HR-MS/MS. Plasma lipidomic signatures differed significantly across treatment stages. Specifically, the lipidomic profile prior to surgery was distinct from those at subsequent stages, demonstrating increased compound abundance of numerous lipids prior to surgery that are decreased at subsequent stages, including linolenic acid (fold change 2.58, p=4.21x10-11), behenic acid (fold change 2.09, p=9.3x10-10), and linolenic acid (fold change 4.44, p=5.83x10-6). Random Forest modeling could predict pre-surgical samples with 85.7% accuracy. Plasma lipidomics shows promise as a liquid biopsy approach for monitoring glioblastoma treatment. The distinct lipidomic profile observed prior to surgery suggests potential for early detection.
- Open Access
- 17 February 2023
- Published by MDPI AG in Metabolites
- Vol. 13 (2) , 299
Application of Machine Learning to Metabolomic Profile Characterization in Glioblastoma Patients Undergoing Concurrent Chemoradiation
We here characterize changes in metabolite patterns in glioblastoma patients undergoing surgery and concurrent chemoradiation using machine learning (ML) algorithms to characterize metabolic changes during different stages of the treatment protocol. We examined 105 plasma specimens (before surgery, 2 days after surgical resection, before starting concurrent chemoradiation, and immediately after chemoradiation) from 36 patients with isocitrate dehydrogenase (IDH) wildtype glioblastoma. Untargeted GC-TOF mass spectrometry-based metabolomics was used given its superiority in identifying and quantitating small metabolites; this yielded 157 structurally identified metabolites. Using Multinomial Logistic Regression (MLR) and GradientBoostingClassifier (GB Classifier), ML models classified specimens based on metabolic changes. The classification performance of these models was evaluated using performance metrics and area under the curve (AUC) scores. Comparing post-radiation to pre-radiation showed increased levels of 15 metabolites: glycine, serine, threonine, oxoproline, 6-deoxyglucose, gluconic acid, glycerol-alpha-phosphate, ethanolamine, propyleneglycol, triethanolamine, xylitol, succinic acid, arachidonic acid, linoleic acid, and fumaric acid. After chemoradiation, a significant decrease was detected in 3-aminopiperidine 2,6-dione. An MLR classification of the treatment phases was performed with 78% accuracy and 75% precision (AUC = 0.89). The alternative GB Classifier algorithm achieved 75% accuracy and 77% precision (AUC = 0.91). Finally, we investigated specific patterns for metabolite changes in highly correlated metabolites. We identified metabolites with characteristic changing patterns between pre-surgery and post-surgery and post-radiation samples. To the best of our knowledge, this is the first study to describe blood metabolic signatures using ML algorithms during different treatment phases in patients with glioblastoma. A larger study is needed to validate the results and the potential application of this algorithm for the characterization of treatment responses.
- 17 February 2023
- Published by MDPI AG in Metabolites
- Vol. 13 (2) , 299
Open AccessApplication of Machine Learning to Metabolomic Profile Characterization in Glioblastoma Patients Undergoing Concurrent Chemoradiation
We here characterize changes in metabolite patterns in glioblastoma patients undergoing surgery and concurrent chemoradiation using machine learning (ML) algorithms to characterize metabolic changes during different stages of the treatment protocol. We examined 105 plasma specimens (before surgery, 2 days after surgical resection, before starting concurrent chemoradiation, and immediately after chemoradiation) from 36 patients with isocitrate dehydrogenase (IDH) wildtype glioblastoma. Untargeted GC-TOF mass spectrometry-based metabolomics was used given its superiority in identifying and quantitating small metabolites; this yielded 157 structurally identified metabolites. Using Multinomial Logistic Regression (MLR) and GradientBoostingClassifier (GB Classifier), ML models classified specimens based on metabolic changes. The classification performance of these models was evaluated using performance metrics and area under the curve (AUC) scores. Comparing post-radiation to pre-radiation showed increased levels of 15 metabolites: glycine, serine, threonine, oxoproline, 6-deoxyglucose, gluconic acid, glycerol-alpha-phosphate, ethanolamine, propyleneglycol, triethanolamine, xylitol, succinic acid, arachidonic acid, linoleic acid, and fumaric acid. After chemoradiation, a significant decrease was detected in 3-aminopiperidine 2,6-dione. An MLR classification of the treatment phases was performed with 78% accuracy and 75% precision (AUC = 0.89). The alternative GB Classifier algorithm achieved 75% accuracy and 77% precision (AUC = 0.91). Finally, we investigated specific patterns for metabolite changes in highly correlated metabolites. We identified metabolites with characteristic changing patterns between pre-surgery and post-surgery and post-radiation samples. To the best of our knowledge, this is the first study to describe blood metabolic signatures using ML algorithms during different treatment phases in patients with glioblastoma. A larger study is needed to validate the results and the potential application of this algorithm for the characterization of treatment responses.
- 10 January 2019
- Published by Elsevier in World Neurosurgery
- Vol. 124, 101-109
Glioblastoma Multiforme of the Conus Medullaris—Management Strategies and Complications
- 10 January 2019
- Published by Elsevier in World Neurosurgery
- Vol. 124, 101-109
Glioblastoma Multiforme of the Conus Medullaris—Management Strategies and Complications